Anaphylactoid reaction considered ciprofloxacin related: a case report and literature review.
BACKGROUND
Although ciprofloxacin is a generally well-tolerated fluoroquinolone antibiotic, serious and life-threatening adverse events such as anaphylaxis and pulmonary edema have been described with its use. However, there is a lack of data in the scientific literature regarding these events.


OBJECTIVE
This report describes a case of an anaphylactoid reaction, considered probably ciprofloxacin related, that manifested as angioedema and later as pulmonary edema. This report also summarizes the available scientific evidence regarding the epidemiology, pathogenesis, and outcome of ciprofloxacin-associated anaphylactoid reactions.


METHODS
Previously reported cases were identified using a search of MEDLINE and EMBASE (years: 1960-June 2009; English-language articles; search terms: ciprofloxacin, anaphylactoid reaction, anaphylaxis, angioedema, and pulmonary edema). The references cited in these articles were examined to identify additional reports. CASE SUMMARY/RESULTS: A 25-year-old healthy white woman with a weight of 65 kg and normal renal function presented with pyelonephritis. She was administered ciprofloxacin 500 mg BID PO and ibuprofen 400 mg q6h PO as needed for pain control. The following day, angioedema and pulmonary edema developed and were thought to be probably associated with ciprofloxacin use (Naranjo adverse drug reaction probability scale score, 6). Ciprofloxacin treatment was discontinued and supportive care with ceftriaxone 1 g/d IV was provided, and the patient recovered after 1 week of hospitalization. The adverse drug reactions associated with the intake of fluoroquinolones most commonly affect the gastrointestinal system, central nervous system, and skin. The literature search identified 64 cases of anaphylactoid reaction considered probably ciprofloxacin related. Forty-two of these cases were described in large studies, with no detailed data reported. Detailed information on the dose of ciprofloxacin, the time period between ciprofloxacin administration and anaphylactoid reaction, clinical manifestations, and outcomes of these reactions was available in 22 cases described in case reports. Twelve of these cases were described in HIV- patients; 10 cases were described in HIV+ patients. All of the patients recovered, with the exception of 2 patients with HIV infection, who died (unknown cause of death in 1 case and toxoplasma encephalitis in the other case). Fourteen patients (including all of the patients with HIV infection) required hospitalization in the intensive care unit. According to the manufacturer of ciprofloxacin, pulmonary edema has been described as an adverse event associated with ciprofloxacin in <1% of treated patients. However, a search of the MEDLINE and EMBASE databases did not identify any documented reports of ciprofloxacin-associated pulmonary edema.


CONCLUSIONS
The patient described in this case report experienced an anaphylactoid reaction likely associated with ciprofloxacin use. Although anaphylactoid/ anaphylactic reactions are uncommon (<5% of cases) adverse events associated with ciprofloxacin and other fluoroquinolones, clinicians should be aware of this potentially life-threatening event, which might also lead to pulmonary edema even in the setting of normal renal function.
Kelesidis
Theodoros
T
Department of Medicine, Caritas St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02135, USA. tkelesid@gmail.com
Fleisher
Jorge
J
Tsiodras
Sotirios
S
D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced* / Q000175:diagnosis; D000799:Angioedema / Q000175:diagnosis; D000890:Anti-Infective Agents / Q000009:adverse effects*; D002939:Ciprofloxacin / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000209:etiology; D005260:Female; D006801:Humans; D011654:Pulmonary Edema / Q000175:diagnosis
D000890:Anti-Infective Agents; D002939:Ciprofloxacin
J Investig Allergol Clin Immunol. 2008;18(5):350-6
18973098
Pediatr Infect Dis J. 1991 Feb;10(2):164-5
2062612
Ann Intern Med. 1995 Mar 1;122(5):396-7
7847662
Respiration. 2007;74(6):697
16205045
Eur J Pediatr. 2006 Aug;165(8):573-4
16547727
Drug Saf. 2006;29(11):1087-100
17061914
Ann Pharmacother. 1993 Nov;27(11):1404
8286820
J Antimicrob Chemother. 1990 Dec;26 Suppl F:25-9
2292542
Drug Saf. 2005;28(6):547-56
15924506
Allergy. 1997 Apr;52(4):432-5
9188926
J Allergy Clin Immunol. 1996 Jun;97(6):1426-7
8648046
Ann Pharmacother. 1997 Jan;31(1):119-20
8997481
Clin Ther. 2004 Jul;26(7):940-50
15336463
Curr Opin Allergy Clin Immunol. 2003 Aug;3(4):275-81
12865771
Drug Saf. 2006;29(5):449-59
16689558
J Allergy Clin Immunol. 2004 Jan;113(1):155-60
14713922
Pharmacotherapy. 2001 Oct;21(10 Pt 2):253S-272S
11642691
BMJ. 1989 Mar 4;298(6673):605
2495139
Ann Pharmacother. 2003 Jul-Aug;37(7-8):1018-23
12841811
Drug Saf. 2007;30(8):705-13
17696583
Ann Intern Med. 1989 Dec 15;111(12):1041-3
2596772
Curr Opin Allergy Clin Immunol. 2001 Aug;1(4):311-6
11964706
Allergy. 2007 Aug;62(8):842-56
17620062
MMWR Morb Mortal Wkly Rep. 2001 Nov 9;50(44):973-6
11724150
Acta Derm Venereol. 2006;86(6):523-7
17106600
Allergy. 1993 Jul;48(5):388-90
8368469
Therapie. 1996 Jul-Aug;51(4):417-8
8953820
Postgrad Med J. 1995 May;71(835):318
7596948
Ann Pharmacother. 1992 Sep;26(9):1081-4
1421669
J Am Acad Dermatol. 1992 Feb;26(2 Pt 1):256-7
1552063
West J Med. 1990 Nov;153(5):563-4
2260307
Clin Ther. 2000 Jul;22(7):798-817; discussion 797
10945507
Pediatr Infect Dis J. 1999 Jun;18(6):563-4
10391195
Int J STD AIDS. 1997 Nov;8(11):707-8
9363547
Lancet. 1989 Apr 29;1(8644):955-6
2565438